SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors debate the impact of Warren Buffett's transition away from active leadership and the company's decision to maintain record cash reserves rather than deploying capital into the current market rally. Community discussion centers on frustration over stagnant performance compared to broader indices, with many investors actively questioning the future direction of the conglomerate under CEO Greg Abel.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending as members of the community point to recent Google research papers highlighting the protocol's post-quantum cryptography features as a potential long-term catalyst. While some investors remain cautious due to historical price performance, others are actively discussing institutional adoption narratives and technical developments as reasons to continue building their positions.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending as the community reacts to the announced preliminary design for the Phase 3 clinical trial of its lead candidate, CAD-1005, for Heparin-Induced Thrombocytopenia. Investors are actively debating the company's long-term clinical prospects versus concerns regarding ongoing cash burn and the potential for future equity offerings.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is trending following a strong quarterly earnings report that featured an EPS beat and raised full-year guidance, driven by significant momentum in its platform and advertising business. Investors and community members are actively debating the stock's long-term valuation and potential for further institutional upgrades, as the company reaches a milestone of 100 million streaming households.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is trending as investors debate whether the stock is a legitimate play on the critical indium phosphide supply chain bottleneck for AI infrastructure or an overvalued Chinese-led pump-and-dump scheme. Community discussion is polarized, with some highlighting high institutional interest and potential for parabolic gains, while critics point to massive insider selling, negative earnings, and concerns over significant upcoming share dilution.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay shares are experiencing heightened activity driven by a circulating rumor of a potential acquisition by GameStop, sparking intense debate across the community regarding the feasibility of such a deal given the massive valuation disparity. While retail investors remain divided on the possibility of a merger, the speculative frenzy has fueled significant volatility, prompting active discussions about the platform's long-term e-commerce strategy and potential for a strategic pivot.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently trending as investors focus on the potential of its lead asset, soquelitinib, following positive analyst price target initiations and anticipation surrounding upcoming data readouts. The community remains deeply divided, with bulls highlighting the drug's oral delivery and unique mechanism as a buyout candidate, while bears point to the stock's recent volatility and the risks inherent in early-stage clinical trials.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors weigh the stock's long-term growth potential against market volatility driven by regional geopolitical tensions and evolving natural gas supply constraints. The community is actively debating whether the current price represents a buying opportunity ahead of upcoming earnings or if it will continue to trade in a range bound by persistent rumors regarding regional stability.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is drawing significant community attention as it navigates a complex retail landscape, balancing news of its nationwide digital price tag rollout with mixed sentiment regarding its current valuation multiples. Investors are actively debating whether its status as a defensive 'safe haven' remains justified given rising operational pressures and ongoing insider activity.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending as investors monitor ongoing technical consolidation and institutional accumulation ahead of the upcoming earnings release. The community remains divided, with bulls pointing toward potential long-term growth and leadership improvements, while critics remain skeptical about the stock's historical performance and the consistency of the current business model.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in ImageneBio, Inc. (NASDAQ:IMA) Increases By 51.7%

ImageneBio, Inc. (NASDAQ:IMA - Get Free Report) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totaling 587,281 shares, a growth of 51.7...

<ul class="summary-bullets"><li>ImageneBio said it plans to use the proceeds to support the development of IMG-007 for alopecia areata and late-stage work in atopic dermatitis.</li><li>The biotech firm is currently conducting its Phase 2b ADAPTIVE trial for IMG-007, with topline results expected in 2027.</li><li>ImageneBio will present the latest data from the study at the Annual Society for Investigative Dermatology Meeting in May.</li></ul>Shares of ImageneBio, Inc. (IMA) surged more than 24% on Monday, crossing their 50-day moving average (50-DMA) for the first time since Feb. 27, 2026, after the biotech firm announced fresh funding from institutional investors in the form of a $30 million private placement.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://in.tradingview.com/chart/teA7VKVN/?symbol=NASDAQ%3AIMA"><img src="https://news.stocktwits-cdn.com/IMA_jpg_91814193cc.webp" alt="IMA.jpg"></a>Source: TradingViewImageneBio said it plans to use the proceeds to support the development of IMG-007 for alopecia areata and late-stage work in atopic dermatitis. The deal involves the sale of pre-funded warrants to purchase over 5.7 million shares at $5.199 per share.The financing round is led by new investor Coastlands Capital, with participation from Trails Edge Capital Partners and existing backers Omega Funds and OrbiMed.<h2 class="st-heading-2">What’s The Latest On Drug To Treat Dermatitis?</h2>ImageneBio is currently conducting a Phase 2b ADAPTIVE trial for IMG-007, with topline results expected in 2027. The study, which began enrollment in mid-2025 across North America, continues to show a favorable safety and tolerability profile, as indicated by a recent blinded review. A Blinded review means the people running a clinical trial do not know which patients are receiving the treatment.IMG-007 has been well tolerated across studies involving more than 150 patients, with no serious safety concerns reported. Reported side effects have been minimal, with very low rates of mild injection-site reactions.The company has also recently submitted a protocol update to expand dosing strategies and explore more patient-friendly treatment schedules. ImageneBio will present the latest data from the study at the Annual Society for Investigative Dermatology Meeting in May.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/IMA">IMA</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.One bullish user said buying the stock was a “no-brainer,” comparing the company’s market cap to the funding amount.<stembedurl>https://stocktwits.com/Jimmytrader35/message/650097652</stembedurl>Another user expects the stock to climb all week.<stembedurl>https://stocktwits.com/Jimmytrader35/message/650131942</stembedurl>Year-to-date, the stock has gained around 5%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cag-stock-crashes-to-near-17-year-lows/cZJ85DBRIun">CAG Stock Crashes To Near 17-Year Lows, But Retail Sees ‘Buying Opportunity Of A Decade’</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

IMA Stock Surges 24%, Breaks 50-DMA For First Time Since February – What's Driving The Rally?

ImageneBio shares jumped to their highest levels in more than a month after the company announced a $30 million fundraising from institutional investors.

Equity

ImageneBio $30 Million Private Placement Ignites Stock

ImageneBio shares rise after a $30 million private placement to advance IMG-007 development for atopic dermatitis and alopecia areata.read more...

ImageneBio (NASDAQ:IMA) Stock Price Down 8.5%  - Here's Why

ImageneBio (NASDAQ:IMA) Shares Down 8.5% - Here's What Happened...

Atlas Venture Life Science Advisors LLC Buys New Position in ImageneBio, Inc. $IMA

Atlas Venture Life Science Advisors LLC bought a new position in shares of ImageneBio, Inc. (NASDAQ:IMA - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F...

Wall Street Zen Upgrades ImageneBio (NASDAQ:IMA) to "Hold"

Wall Street Zen upgraded ImageneBio from a "strong sell" rating to a "hold" rating in a report on Saturday...

BML Capital Management LLC Makes New Investment in ImageneBio, Inc. $IMA

BML Capital Management LLC purchased a new position in ImageneBio, Inc. (NASDAQ:IMA - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities...

ImageneBio (NASDAQ:IMA) Shares Up 2.4% - Still a Buy?

ImageneBio (NASDAQ:IMA) Stock Price Up 2.4% - Still a Buy...

ImageneBio (NASDAQ:IMA) Trading Up 0.5% - Should You Buy?

ImageneBio (NASDAQ:IMA) Shares Up 0.5% - Here's Why...

Insider Buying: ImageneBio (NASDAQ:IMA) Director Acquires 16,000 Shares of Stock

ImageneBio, Inc. (NASDAQ:IMA - Get Free Report) Director Joseph Slattery acquired 16,000 shares of the company's stock in a transaction on Wednesday, December 24th. The shares were bought at an...

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. It focuses on the development of new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The company was founded in February 2016, and is headquartered in San Diego, CA.

Current Price	$5.66
Prev Close	$6.02
Open	$5.97
Dividend Yield	0.00%
50-Day Moving Average	$5.77
Beta	0.85
Avg. Volume	964,989.58
PE Ratio	-0.88

52-Week High	$18.00
52-Week Low	$3.94
Market Capitalization	$63.31M
EPS (Annual)	-$9.64
Price to Book	0.48
Revenue Per Employee	$53,333.33

IMA
ImageneBio, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IMA News

IMAImageneBio, Inc.